title: Key residues controlling phenacetin metabolism by human cytochrome P450 2A enzymes.
abstract: Cytochrome P450s (P450s) metabolize a large number of diverse substrates with specific regio- and stereospecificity. A number of compounds, including nicotine, cotinine, and aflatoxin B(1), are metabolites of the 94% identical CYP2A13 and CYP2A6 enzymes but at different rates. Phenacetin and 4-aminobiphenyl were identified as substrates of human cytochromes P450 1A2 and 2A13 but not of CYP2A6. The purpose of this study was to identify active site amino acids that are responsible for CYP2A substrate specificity using phenacetin as a structural probe. Ten amino acid residues that differ in the CYP2A13 and CYP2A6 active sites were exchanged between the two enzymes. Phenacetin binding revealed that the six substitution, CYP2A13 S208I, A213S, F300I, A301G, M365V, and G369S decreased phenacetin affinity. Although incorporation of individual CYP2A13 residues into CYP2A6 had little effect on this enzyme's very low levels of phenacetin metabolism, the combination of double, triple, and quadruple substitutions at positions 208, 300, 301, and 369 increasingly endowed CYP2A6 with the ability to metabolize phenacetin. Enzyme kinetics revealed that the CYP2A6 I208S/I300F/G301A/S369G mutant protein O-deethylated phenacetin with a K(m) of 10.3 muM and a k(cat) of 2.9 min(-1), which compare very favorably with those of CYP2A13 (K(m) of 10.7 muM and k(cat) of 3.8 min(-1)). A 2.15 A crystal structure of the mutant CYP2A6 I208S/I300F/G301A/S369G protein with phenacetin in the active site provided a structural rationale for the differences in phenacetin metabolism between CYP2A6 and CYP2A13.
authors.affiliation: Department of Medicinal Chemistry, University of Kansas, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
authors.forename: Natasha M
authors.initials: NM
authors.lastname: DeVore
authors.forename: Brian D
authors.initials: BD
authors.lastname: Smith
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Urban
authors.forename: Emily E
authors.initials: EE
authors.lastname: Scott
mesh_terms: D019943:Amino Acid Substitution; D000596:Amino Acids / Q000235:genetics / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D002384:Catalysis; D020134:Catalytic Domain; D065637:Cytochrome P-450 CYP2A6; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D008968:Molecular Conformation; D010615:Phenacetin / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D013053:Spectrophotometry; D013250:Steroid Hydroxylases / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D013379:Substrate Specificity / Q000235:genetics
chemical_list: D000596:Amino Acids; D011994:Recombinant Proteins; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; C414206:CYP2A13 protein, human; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6; C029009:steroid hormone 7-alpha-hydroxylase; D010615:Phenacetin
references.citation: Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
references.pmid: 15299374
references.citation: Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
references.pmid: 16369096
references.citation: Arch Biochem Biophys. 2007 Aug 15;464(2):197-206
references.pmid: 17540336
references.citation: Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
references.pmid: 15299926
references.citation: Curr Drug Metab. 2006 Dec;7(8):939-48
references.pmid: 17168693
references.citation: Int J Cancer. 2006 Dec 1;119(11):2520-6
references.pmid: 16988941
references.citation: J Mol Graph. 1990 Mar;8(1):52-6, 29
references.pmid: 2268628
references.citation: Int J Cancer. 2006 Jun 1;118(11):2665-71
references.pmid: 16385575
references.citation: Arch Biochem Biophys. 2004 Jul 15;427(2):143-53
references.pmid: 15196988
references.citation: Xenobiotica. 2007 Dec;37(12):1439-49
references.pmid: 17922361
references.citation: J Biol Chem. 2007 Jun 8;282(23):17306-13
references.pmid: 17428784
references.citation: Nat Struct Mol Biol. 2005 Sep;12(9):822-3
references.pmid: 16086027
references.citation: Drug Metab Dispos. 2007 Mar;35(3):335-9
references.pmid: 17178771
references.citation: Xenobiotica. 1985 Nov;15(11):915-27
references.pmid: 4082632
references.citation: Acta Crystallogr D Biol Crystallogr. 1994 Mar 1;50(Pt 2):178-85
references.pmid: 15299456
references.citation: Biochimie. 1996;78(8-9):685-94
references.pmid: 9010596
references.citation: J Biol Chem. 2005 Dec 9;280(49):41090-100
references.pmid: 16215230
references.citation: Cancer Res. 2000 Sep 15;60(18):5074-9
references.pmid: 11016631
references.citation: Drug Metab Dispos. 2005 Feb;33(2):258-61
references.pmid: 15528319
references.citation: Chem Res Toxicol. 2008 Mar;21(3):720-5
references.pmid: 18266326
references.citation: Drug Metab Dispos. 2004 Dec;32(12):1516-21
references.pmid: 15333516
references.citation: J Biol Chem. 2007 May 11;282(19):14348-55
references.pmid: 17311915
references.citation: Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):48-57
references.pmid: 16369093
references.citation: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
references.pmid: 15572765
references.citation: Xenobiotica. 1985 Feb;15(2):149-64
references.pmid: 4002737
references.citation: J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
references.pmid: 19461840